New treatment options for chronic back pain: An Overview of Emerging Clinical Advancements and Regulatory Approvals

Chronic low back pain (CLBP) is estimated to affect more than half a billion people globally, often resulting in significant disability and reduced quality of life 1. Recent clinical data highlights a shift toward non-opioid alternatives and minimally invasive technologies designed to address the underlying causes of pain rather than merely masking symptoms. This report examines the latest regulatory authorizations and clinical trial outcomes for these emerging therapies.

Pharmacological Breakthroughs in Non-Opioid Pain Management

One of the most significant recent developments in the pharmacological sector is the introduction of VER-01, a pharmaceutical-grade full-spectrum extract derived from a specific Cannabis sativa strain known as DKJ127 1. In a Phase 3 randomized placebo-controlled trial involving 820 adults, VER-01 achieved its primary endpoint by demonstrating a mean pain reduction of -1.9 points on the numeric rating scale (NRS) over a 12-week period 1. Researchers noted that these effects were sustained through long-term extension phases, providing a potentially durable alternative to traditional analgesics.

Marketed as Exilby, this treatment received marketing authorization in Germany and Austria in June 2026 for treating chronic low back pain with a neuropathic or radicular component 2. Clinical comparisons have indicated that VER-01 may offer superior pain reduction and improved gastrointestinal tolerability when compared directly to opioid-based regimens 3. The U.S. Food and Drug Administration (FDA) has also granted Breakthrough Therapy Designation to the compound, a status intended to expedite the development of medicines that show potential for substantial improvement over existing therapies 4.

Advancements in Basivertebral Nerve Ablation

For patients suffering from vertebrogenic pain, which often stems from damaged vertebral endplates, basivertebral nerve ablation (BVNA) has emerged as a targeted interventional option 5. This procedure involves the precise thermal destruction of the basivertebral nerve to interrupt pain signaling 6. Research published by the Yale School of Medicine suggests that BVNA can provide early and sustained relief for patients who have not responded to conservative management 7.

Clinical outcomes associated with BVNA indicate notable success rates, with some studies reporting that at least 50% pain reduction was achieved by a significant portion of participants at the six-month mark 6. Recent strategic agreements have expanded the availability of these systems, such as the ViaVerte system, which utilizes a physician-controlled steerable mechanism for precise nerve targeting 5. Data indicates that successful ablation is often associated with a reduction in subsequent spine-related procedures and a decrease in opioid reliance 6.

Peripheral Nerve Stimulation and Neuromodulation

Neuromodulation remains a cornerstone of modern interventional pain care, with peripheral nerve stimulation (PNS) gaining traction as a temporary, minimally invasive solution. The SPRINT PNS system, for example, is a 60-day treatment that does not require a permanent implant 8. Analysis of clinical trials showed that participants who received the treatment as prescribed were three times more likely to achieve meaningful pain relief compared to those with inconsistent delivery 9.

Furthermore, insurance coverage for these technologies is expanding, with major providers like Aetna recently designating certain PNS systems as medically necessary for intractable neuropathic pain 8. This policy shift reflects the growing body of evidence supporting the use of neuromodulation to improve daily function and reduce chronic pain syndrome symptoms 10.

Regenerative and Intradiscal Interventions

Regenerative medicine focuses on repairing damaged spinal structures rather than just managing discomfort. One such approach involves the use of viable nucleus pulposus (NP) allografts, which are injected into the disc space to supplement degenerated tissue 11. A retrospective study using Medicare data compared 1,804 patients receiving the VIA Disc NP allograft to a matched conservative care group, finding that the allograft approach may serve as an effective first-line intervention for discogenic pain 11.

In the field of cellular therapy, rexlemestrocel-L is currently under investigation in Phase 3 trials for chronic low back pain associated with degenerative disc disease 12. This therapy uses allogeneic stromal cells to target the inflammatory processes that drive disc breakdown 12. Preliminary results from earlier trials suggested that a single intra-discal injection could result in clinically meaningful pain reductions lasting up to three years, potentially offering a long-term solution for patients who wish to avoid invasive surgery 12.

Non-Invasive Brain Stimulation and Digital Therapeutics

Emerging research is also exploring the role of the central nervous system in chronic pain through non-invasive brain stimulation (NIBS). Techniques such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) have been evaluated for their ability to modulate pain perception 13. A systematic review of 21 randomized controlled trials found that NIBS significantly reduced pain intensity and disability levels compared to sham interventions 13.

Parallel to physical interventions, digital therapeutics are being integrated into standard care. Telehealth mindfulness programs and virtual reality (VR) systems have shown efficacy in reducing the burden of chronic pain by addressing the psychological and cognitive aspects of the condition 14. The FDA has previously authorized VR-based systems specifically for the reduction of lower back pain, highlighting the utility of behavioral and cognitive tools in a multidisciplinary treatment plan 15.

Acoustic Wave Therapy and Multimodal Approaches

Extracorporeal Shockwave Therapy (ESWT) uses high-energy acoustic waves to trigger biological responses at the cellular level, a process known as mechanotransduction 16. This therapy is often combined with conventional physical therapy to improve outcomes for patients with chronic low back pain 17. By stimulating blood flow and tissue remodeling, ESWT aims to restart the body’s natural healing mechanisms in areas of chronic inflammation or scar tissue 16.

While these advancements offer new possibilities, medical experts emphasize that a 360-degree view of patient care is essential. Associated risks, such as transient adverse events like dizziness or sedation in pharmacological trials, or the need for precise anatomical targeting in interventional procedures, remain critical considerations 1. Eligibility for these treatments often depends on specific diagnostic criteria, such as the presence of a neuropathic component or evidence of vertebral endplate damage 2. As the landscape of chronic pain management evolves, the integration of these diverse modalities may provide more personalized and effective pathways for long-term relief.

Sources

1. Nature Medicine: Full-spectrum extract for chronic low back pain Phase 3 trial
2. The Cannabis Pages: European Market Approvals for chronic back pain drug
3. The Cannigma: Cannabis Drug vs Opioids Clinical Trial Analysis
4. PR Newswire: FDA Breakthrough Therapy Designation for VER-01
5. Morningstar: Medtronic and Merit Medical Agreement for ViaVerte System
6. Rheumatology Advisor: Basivertebral Nerve Ablation Outcomes
7. Yale School of Medicine: Basivertebral Nerve Ablation Relief Report
8. GlobeNewswire: Aetna National Coverage for SPRINT PNS System
9. GlobeNewswire: SPRINT PNS RESET Clinical Trial Data
10. Doral Health: Modern Spinal Cord Stimulation and Daily Function
11. Dove Medical Press: Intradiscal Nucleus Pulposus Allograft Medicare Claims Study
12. BioSpace: Mesoblast Phase 3 Trial for Chronic Low Back Pain
13. Journal of NeuroEngineering and Rehabilitation: NIBS Meta-analysis for CLBP
14. News-Medical: Telehealth mindfulness program for chronic pain
15. U.S. Food and Drug Administration: Authorization of Virtual Reality System for Back Pain
16. Chattanooga Non-Surgical Orthopedics: Shockwave Therapy Biological Mechanisms
17. Frontiers in Physiology: Efficacy of ESWT combined with Physical Therapy